ISAL 2019 | Bispecific antibodies for R/R AML: ongoing clinical trials

John DiPersio

Bispecific antibodies are moving from strength to strength, with a multitude in clinical trials. Here, John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, discusses the bispecific antibodies under investigation for relapsed/refractory acute myeloid leukemia (AML), typically targeting CD123, CD33 or CLL1. Prof. DiPersio was speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter